U.S. pharma large copyright scrapped two experimental weight loss tablets previous calendar year—a once-day-to-day capsule, lotiglipron, due to elevated liver enzymes and also a twice-daily tablet, danuglipron, as a consequence of potent Unintended effects—but CEO Albert Bourla has said the company is determined to “Perform and gain” while